These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

92 related items for PubMed ID: 18436362

  • 21. The effectiveness of a cognitive-behavioral intervention for pathological gambling: a country-wide study.
    Pasche SC, Sinclair H, Collins P, Pretorius A, Grant JE, Stein DJ.
    Ann Clin Psychiatry; 2013 Nov; 25(4):250-6. PubMed ID: 24199214
    [Abstract] [Full Text] [Related]

  • 22. The Gambling Symptom Assessment Scale (G-SAS): a reliability and validity study.
    Kim SW, Grant JE, Potenza MN, Blanco C, Hollander E.
    Psychiatry Res; 2009 Mar 31; 166(1):76-84. PubMed ID: 19200607
    [Abstract] [Full Text] [Related]

  • 23. Self-reported and neuropsychological measures of impulsivity in pathological gambling.
    Fuentes D, Tavares H, Artes R, Gorenstein C.
    J Int Neuropsychol Soc; 2006 Nov 31; 12(6):907-12. PubMed ID: 17064453
    [Abstract] [Full Text] [Related]

  • 24. [Antiepileptic drugs in the control of the impulses disorders].
    Roncero C, Rodríguez-Urrutia A, Grau-López L, Casas M.
    Actas Esp Psiquiatr; 2009 Nov 31; 37(4):205-12. PubMed ID: 19927233
    [Abstract] [Full Text] [Related]

  • 25. Quetiapine as an adjunctive pharmacotherapy for the treatment of non-remitting generalized anxiety disorder: a flexible-dose, open-label pilot trial.
    Katzman MA, Vermani M, Jacobs L, Marcus M, Kong B, Lessard S, Galarraga W, Struzik L, Gendron A.
    J Anxiety Disord; 2008 Dec 31; 22(8):1480-6. PubMed ID: 18455360
    [Abstract] [Full Text] [Related]

  • 26. Cognitive dysfunctions and pathological gambling in patients with Parkinson's disease.
    Santangelo G, Vitale C, Trojano L, Verde F, Grossi D, Barone P.
    Mov Disord; 2009 Apr 30; 24(6):899-905. PubMed ID: 19205072
    [Abstract] [Full Text] [Related]

  • 27. Once-daily extended-release levetiracetam as adjunctive treatment of partial-onset seizures in patients with epilepsy: a double-blind, randomized, placebo-controlled trial.
    Peltola J, Coetzee C, Jiménez F, Litovchenko T, Ramaratnam S, Zaslavaskiy L, Lu ZS, Sykes DM, Levetiracetam XR N01235 Study Group.
    Epilepsia; 2009 Mar 30; 50(3):406-14. PubMed ID: 19317886
    [Abstract] [Full Text] [Related]

  • 28. Individual versus group cognitive behavioral treatment for obsessive-compulsive disorder: follow up.
    Jaurrieta N, Jiménez-Murcia S, Alonso P, Granero R, Segalàs C, Labad J, Menchón JM.
    Psychiatry Clin Neurosci; 2008 Dec 30; 62(6):697-704. PubMed ID: 19068007
    [Abstract] [Full Text] [Related]

  • 29. Adverse event load in bipolar participants receiving either carbamazepine immediate-release or extended-release capsules: a blinded, randomized study.
    El-Mallakh RS, Salem MR, Chopra AS, Mickus GJ, Penagaluri P.
    Int Clin Psychopharmacol; 2009 May 30; 24(3):145-9. PubMed ID: 19367153
    [Abstract] [Full Text] [Related]

  • 30. Correlation of increase in phosphene threshold with reduction of migraine frequency: observation of levetiracetam-treated subjects.
    Young W, Shaw J, Bloom M, Gebeline-Myers C.
    Headache; 2008 May 30; 48(10):1490-8. PubMed ID: 19076647
    [Abstract] [Full Text] [Related]

  • 31. Topiramate versus fluvoxamine in the treatment of pathological gambling: a randomized, blind-rater comparison study.
    Dannon PN, Lowengrub K, Gonopolski Y, Musin E, Kotler M.
    Clin Neuropharmacol; 2005 May 30; 28(1):6-10. PubMed ID: 15711432
    [Abstract] [Full Text] [Related]

  • 32. Dentinal hypersensitivity: a 12-week study of a novel dentifrice delivery system comparing different brushing times and assessing the efficacy for hard-to-reach molar teeth.
    Leight RS, Sufi F, Gross R, Mason SC, Barlow AP.
    J Clin Dent; 2008 May 30; 19(4):147-53. PubMed ID: 19278086
    [Abstract] [Full Text] [Related]

  • 33. Augmentation of antidepressants with perospirone for treatment-resistant major depressive disorder.
    Sato Y, Yasui-Furukori N, Nakagami T, Saito M, Kaneko S.
    Prog Neuropsychopharmacol Biol Psychiatry; 2009 Apr 30; 33(3):416-8. PubMed ID: 19166896
    [Abstract] [Full Text] [Related]

  • 34. Remission in schizophrenia: one-year Italian prospective study of risperidone long-acting injectable (RLAI) in patients with schizophrenia or schizoaffective disorder.
    Rossi A, Bagalà A, Del Curatolo V, Scapati F, Bernareggi MM, Giustra MG, Risperidone Long-Acting Trial Investigators (R-LAI).
    Hum Psychopharmacol; 2009 Oct 30; 24(7):574-83. PubMed ID: 19790173
    [Abstract] [Full Text] [Related]

  • 35. Efficacy and tolerability of two formulations of ramipril in Korean adults with mild to moderate essential hypertension: an 8-week, multicenter, prospective, randomized, open-label, parallel-group noninferiority trial.
    Kim SH, Chung WY, Zo JH, Kim MA, Chang HJ, Cho YS, Youn TJ, Chae IH, Choi DJ, Gwak JJ, Lee HY, Park JS, Kang HJ, Kim YJ, Kim HS.
    Clin Ther; 2009 May 30; 31(5):988-98. PubMed ID: 19539099
    [Abstract] [Full Text] [Related]

  • 36. A single-blind study of 'as-needed' ecopipam for gambling disorder.
    Grant JE, Odlaug BL, Black DW, Fong T, Davtian M, Chipkin R, Kim SW.
    Ann Clin Psychiatry; 2014 Aug 30; 26(3):179-86. PubMed ID: 25166480
    [Abstract] [Full Text] [Related]

  • 37. Does early improvement triggered by antidepressants predict response/remission? Analysis of data from a naturalistic study on a large sample of inpatients with major depression.
    Henkel V, Seemüller F, Obermeier M, Adli M, Bauer M, Mundt C, Brieger P, Laux G, Bender W, Heuser I, Zeiler J, Gaebel W, Mayr A, Möller HJ, Riedel M.
    J Affect Disord; 2009 Jun 30; 115(3):439-49. PubMed ID: 19027961
    [Abstract] [Full Text] [Related]

  • 38. Severity of gambling is associated with severity of depressive symptoms in pathological gamblers.
    Rømer Thomsen K, Callesen MB, Linnet J, Kringelbach ML, Møller A.
    Behav Pharmacol; 2009 Sep 30; 20(5-6):527-36. PubMed ID: 19654506
    [Abstract] [Full Text] [Related]

  • 39. Efficacy and tolerability of intranasal fentanyl spray 50 to 200 microg for breakthrough pain in patients with cancer: a phase III, multinational, randomized, double-blind, placebo-controlled, crossover trial with a 10-month, open-label extension treatment period.
    Kress HG, Orońska A, Kaczmarek Z, Kaasa S, Colberg T, Nolte T.
    Clin Ther; 2009 Jun 30; 31(6):1177-91. PubMed ID: 19695386
    [Abstract] [Full Text] [Related]

  • 40. Effectiveness of carbamazepine for benzodiazepine-resistant impulsive aggression in a patient with frontal infarctions.
    Pae CU.
    Psychiatry Clin Neurosci; 2008 Aug 30; 62(4):483. PubMed ID: 18778450
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 5.